ArticleHaematologica2018
A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- 15-PGDH inhibition enhances hematopoietic regeneration during aging.Stem cells (Dayton, Ohio) · 2025Article
- Structure and transport mechanism of the human prostaglandin transporter SLCO2A1.Nature communications · 2025Article
- Prostaglandin EEXCLI journal · 2025Review
- A transcriptome-based risk model in sepsis enables prognostic prediction and drug repositioning.iScience · 2024Article
- Biocomputational screening of natural compounds targeting 15-hydroxyprostaglandin dehydrogenase to improve skeletal muscle during aging.Molecular diversity · 2024Article
- Hair Growth Promoting Effects of 15-Hydroxyprostaglandin Dehydrogenase Inhibitor in Human Follicle Dermal Papilla Cells.International journal of molecular sciences · 2024Article
- Enzymatic Resolution and Decarboxylative Functionalization of α-Sulfinyl Esters.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Article
- Advances in ex vivo expansion of hematopoietic stem and progenitor cells for clinical applications.Frontiers in bioengineering and biotechnology · 2024Review
- Review
- Small molecule inhibitors of 15-PGDH exploit a physiologic induced-fit closing system.Nature communications · 2023Article
- Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration.Journal of medicinal chemistry · 2022Article
- Development and clinical advancement of small molecules forActa pharmaceutica Sinica. B · 2022Review
- Article
- Polymer Microparticles Prolong Delivery of the 15-PGDH Inhibitor SW033291.Pharmaceutics · 2021Article
- Structural Insights into Novel 15-Prostaglandin Dehydrogenase Inhibitors.Molecules (Basel, Switzerland) · 2021Article
- 15-PGDH inhibition activates the splenic niche to promote hematopoietic regeneration.JCI insight · 2021Article
- Role of prostaglandin E2 in tissue repair and regeneration.Theranostics · 2021Review
- Inhibition of 15-PGDH Protects Mice from Immune-Mediated Bone Marrow Failure.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
- Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis.Scientific reports · 2020Article
- A Role for Lipid Mediators in Acute Myeloid Leukemia.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Hematopoietic stem cell transplantation following myeloablative chemotherapy is a curative treatment for many hematopoietic malignancies. However, profound granulocytopenia during the interval between transplantation and marrow recovery exposes recipients to risks of fatal infection, a significant source of transplant-associated morbidity and mortality. We have previously described the discovery of a small molecule, SW033291, that potently inhibits the prostaglandin degrading enzyme 15-PGDH, increases bone marrow prostaglandin E2, and accelerates hematopoietic recovery following murine transplant. Here we describe the efficacy of (+)-SW209415, a second-generation 15-PGDH inhibitor, in an expanded range of models relevant to human transplantation. (+)-SW209415 is 10,000-fold more soluble, providing the potential for intravenous delivery, while maintaining potency in inhibiting 15-PGDH, increasing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.